(NASDAQ: STRO) Sutro Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.33%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.58%.
Sutro Biopharma's earnings in 2025 is -$216,767,000.On average, 12 Wall Street analysts forecast STRO's earnings for 2025 to be -$190,229,697, with the lowest STRO earnings forecast at -$228,605,281, and the highest STRO earnings forecast at -$168,057,062. On average, 12 Wall Street analysts forecast STRO's earnings for 2026 to be -$178,191,567, with the lowest STRO earnings forecast at -$604,886,235, and the highest STRO earnings forecast at -$53,635,233.
In 2027, STRO is forecast to generate -$133,151,594 in earnings, with the lowest earnings forecast at -$325,387,078 and the highest earnings forecast at -$3,575,682.